Jessica R. Kirshner

Regeneron (United States) — United States

Medicine · Health Sciences

22h-index3.5kcitations111works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(57), HER2/EGFR in Cancer Research(33), CAR-T cell therapy research(27), Immunotherapy and Immune Responses(15), Advanced Biosensing Techniques and Applications(14)

Publications111 total

Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumors
Science Advances·2026Open Access
MUC16 as a novel therapeutic target for high-grade endometrial cancer
Gynecologic Oncology·2025
CAR T cells based on fully human T cell receptor–mimetic antibodies exhibit potent antitumor activity in vivo
Science Translational Medicine·2025· 2 citedOpen Access
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2025· 2 cited
A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager
Blood·2024· 3 cited
Establishing an immunocompetent mouse model of CAR T anti-tumor efficacy for studies of therapeutic resistance
The Journal of Immunology·2024
Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
Molecular Cancer Therapeutics·2023
Data from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Figures 1-7 from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Abstract 1780: TCR-T and CAR-T cells targeting HLA-A2/MAGEA4 demonstrate differential tumor control, reflecting co-stimulatory signaling requirements
Cancer Research·2023
Data from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Supplementary Figures 1-7 from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Supplementary Table S2 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S5 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S5 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
2023Open Access
Supplementary Figure S1 - S8 from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Gavin Thurston(27), William C. Olson(15), Marcus P. Kelly(14), Carlos Hickey(12), Frank J. Delfino(11), Sosina Makonnen(11), Jason T. Giurleo(11), Kara Olson(10), Lauric Haber(9), John Lin(9), Eric Smith(8), Richard Tavaré(8), James Barsoum(7), John Bertin(7), Douglas MacDonald(7), Priyanka Ram(7), Marc W. Retter(7), David J. DiLillo(7), Katja Mohrs(7), Dangshe Ma(7)